Functional polymorphism rs710218 in the gene coding GLUT1 protein is associated with in-stent restenosis-Reference-Cited by-同舟云学术

Functional polymorphism rs710218 in the gene coding GLUT1 protein is associated with in-stent restenosis

Published:2015-08 Issue:8 Volume:9 Page:743-750
ISSN:1752-0363
Container-title:Biomarkers in Medicine
language:en
Short-container-title:Biomarkers in Medicine

Author:

Osadnik Tadeusz¹,Strzelczyk Joanna²,Bujak Kamil¹,Reguła Rafał¹,Wasilewski Jarosław¹,Fronczek Martyna²,Kurek Anna¹,Gawlita Marcin¹,Gonera Małgorzata¹,Gierlotka Marek¹,Lekston Andrzej¹,Hawranek Michał¹,Myrda Krzysztof¹,Wiczkowski Andrzej²,Ostrowska Zofia²,Gąsior Mariusz¹,Poloński Lech¹

Affiliation:

1. Medical University of Silesia, School of Medicine with the Division of Dentistry, 3rd Department of Cardiology, Silesian Centre for Heart Diseases, Marii Skłodowskiej Curie Street 9, 41-800 Zabrze, Poland

2. Medical University of Silesia, School of Medicine with the Division of Dentistry, Department of Medical and Molecular Biology, Jordana Street 19, 41-808 Zabrze, Poland

Abstract

Aim: To analyze the association between in-stent restenosis (ISR) and polymorphisms in genes coding IGF-1, IGFBP3, ITGB3 and GLUT1, which play an important role in the smooth muscle cell proliferation and extracellular matrix synthesis – the main components of neointima. Materials & methods: We analyzed 265 patients who underwent bare metal stent implantation. Results: The differences in the occurrence of ISR between genotypes of the analyzed polymorphisms in the IGF-1, IGFBP3 and ITGB3 were not statistically significant. The T/T genotype of the rs710218 polymorphism in the GLUT1 (SLC2A1) gene was more common in the ISR group compared with non-ISR patients (81.1 vs 64.8%; p = 0.02). In a multivariable model the A/A and A/T genotype remained correlated with lower occurrence of ISR (odds ratio: 0.45; 95% CI: 0.21–0.97; p = 0.03). Conclusion: The rs710218 polymorphism in the gene coding GLUT1 protein is a novel risk factor for ISR.

Publisher

Future Medicine Ltd

Subject

Biochemistry (medical),Clinical Biochemistry,Drug Discovery

Link

https://www.futuremedicine.com/doi/pdf/10.2217/BMM.15.36

Reference40 articles.

1. Novel Approaches to Reduce Restenosis

2. The Pathophysiology and Burden of Restenosis

3. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer

4. Normal growth and development in the absence of hepatic insulin-like growth factor I

5. IGF-I and IGFBP-3 Polymorphisms in Relation to Circulating Levels among African American and Caucasian Women

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gamut of glycolytic enzymes in vascular smooth muscle cell proliferation: Implications for vascular proliferative diseases;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-03

2. Polymorphism in the HaeIII single nucleotide polymorphism of the SLC2A1 gene and cardiovascular disease in the early type 2 diabetes mellitus;Diabetes and Vascular Disease Research;2021-09

3. The CTGF gene -945 G/C polymorphism is associated with target lesion revascularization for in-stent restenosis;Experimental and Molecular Pathology;2021-02

4. The role of the I/D polymorphism in the angiotensin-converting enzyme gene in selected cardiovascular diseases;Postępy Higieny i Medycyny Doświadczalnej;2018-08-10

5. Role of Gene Polymorphisms/Haplotypes and Plasma Level of TGF-β1 in Susceptibility to In-Stent Restenosis Following Coronary Implantation of Bare Metal Stent in Chinese Han Patients;International Heart Journal;2018